Carolina Liquid Chemistries Offers FDA Emergency Use Authorized POC COVID-19/Flu A&B Combo Test

Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) has made yet another addition to its Point-of-Care product line by offering the Emergency Use Authorized Status COVID-19/Flu A&B Combo Test from LifeSign LLC (Skillman, NJ, USA).

The Status COVID-19/Flu A&B Combo Test is a lateral flow immunoassay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, Influenza A, and Influenza B directly from nasopharyngeal swab specimens obtained from individuals, who are suspected of respiratory viral infection consistent with COVID-19 and/or influenza by their healthcare provider, within the first five days of onset of symptoms.


To respond effectively to the COVID-19 outbreak, rapid detection of cases, stringent performance assessment, and increase in the current diagnostic capacity are still urgently needed. As the early symptoms of COVID-19 are similar to those of seasonal Influenza A or B, a rapid detection test to specifically diagnose symptomatic patients is urgently needed. The Status COVID-19/Flu A&B Combo Test is intended to aid in the rapid differential diagnosis of Influenza A, B, and SARS-CoV-2 viral infection.

"The Status COVID-19/Flu A&B Combo Test is a vital combination test for the current market. Anytime we can make testing easier, faster, less expensive, and more efficient for the patient and provider, we know we are doing our job," said Phil Shugart, CEO of Carolina Liquid Chemistries Corp.

Related Links:
Carolina Liquid Chemistries, Corp.
LifeSign LLC